Please wait a minute...
J Zhejiang Univ (Med Sci)  2019, Vol. 48 Issue (4): 384-389    DOI: 10.3785/j.issn.1008-9292.2019.08.06
    
Analysis of Alport syndrome induced by type IV collagen alpha 5 gene mutation in two families
YE Qing1(),ZHANG Yingying2,WANG Jingjing2,MAO Jianhua2,*()
1. Clinical Laboratory, the Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China
2. Department of Nephrology, the Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China
Download: HTML( 7 )   PDF(1021KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To investigate genetic characteristics of Alport syndrome. Methods: High-throughput sequencing-based whole exome sequencing was performed in two patients with recurrent unexplained abnormal urinalysis. The pathogenicity of the genetic variations, type of Mendelian genetics, and clinical phenotypes were analysed, and the disease-cause mutations were confirmed in the family members using Sanger sequencing. Results: Two heterozygous splice site mutations of COL4A5 gene c.2147-2A > T (IVS27) and c.646-2A > G (IVS11) (NM_033380) were found in patients of the two families, which showed a co-segregation association with the affected members of the families. Conclusion: Alport syndrome is mainly inherited from direct female patients, and prenatal genetic screening based on amniotic fluid testing can effectively prevent birth defects in patients with a family history of this characteristic phenotype.



Key wordsNephritis, hereditary/genetics      Collagen type Ⅳ/genetics      Chromosomes, human, X      Exons      Mutation      Pedigree      Genetic testing      Phenotype     
Received: 20 July 2019      Published: 30 October 2019
CLC:  R349.3  
  R725  
Corresponding Authors: MAO Jianhua     E-mail: qingye@zju.edu.cn;maojh88@zju.edu.cn
Cite this article:

YE Qing,ZHANG Yingying,WANG Jingjing,MAO Jianhua. Analysis of Alport syndrome induced by type IV collagen alpha 5 gene mutation in two families. J Zhejiang Univ (Med Sci), 2019, 48(4): 384-389.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2019.08.06     OR     http://www.zjujournals.com/med/Y2019/V48/I4/384


Ⅳ型胶原α5链基因突变致奥尔波特综合征两家系遗传学分析

目的: 分析奥尔波特(Alport)综合征的遗传学特征。方法: 对原因不明的反复尿检异常的2名先证者进行基于高通量测序技术的全外显子组测序,通过基因突变的致病性、孟德尔遗传规律和临床表型的综合分析,筛选出致病的基因突变,最后通过Sanger测序在家系成员中验证基因突变。结果: 两个家系中分别鉴定出COL4A5基因上的2个杂合性剪接位点突变:c.2147-2A > T(IVS27)和c.646-2A > G(IVS11)(NM_033380),且这2个杂合突变分别与2个家系的患病成员呈现共分离关联。结论: Alport综合征主要通过女性直系患者遗传,临床上可以通过有效的遗传咨询进行产前诊断。


关键词: 肾炎, 遗传性/遗传学,  胶原Ⅳ型/遗传学,  染色体, 人, X,  外显子,  突变,  系谱,  基因检测,  表型 
Fig 1 Pedigree of the families with X-linked Alport syndrome
Fig 2 Pathological changes in renal tissue of proband of X-linked Alport syndrome
序号 听力 视力 血压(mmHg) 尿红细胞 尿蛋白 尿素(mmol/L) 肌酐(μmol/L) 血白蛋白(g/L) 血球蛋白(g/L) 总胆固醇(mmol/L) 三酰甘油(mmol/L)
1 mmHg=0.133 kPa.
家系1 2 正常 正常 142/90 ++ ++ 5.2 78 39 28 6.2 2.3
5 正常 正常 正常 ++ ++ 3.2 62 34 21 5.7 1.9
6 正常 正常 正常 +++ + 4.1 68 42 31 3.2 1.5
家系2 2 正常 正常 正常 ++ ++ 4.8 54 37 24 5.9 3.2
5 正常 正常 正常 + + 12.5 782 41 30 6.3 1.4
5 正常 正常 正常 +++ ++ 5.7 73 35 22 4.5 1.1
6 正常 正常 正常 +++ + 4.9 41 43 34 4.2 1.6
Tab 1 Clinical data and laboratory examination of two families with Alport syndrome
Fig 3 Sanger sequencing of COL4A5 gene variation locus in proband of X-linked Alport syndrome
[1]   XIU X , YUAN J , DENG X et al. A novel COL4A5 mutation identified in a Chinese Han family using exome sequencing[J]. Biomed Res Int, 2014, 2014 (10): 186048
[2]   GUBLER M , LEVY M , BROYER M et al. Alport's syndrome:A report of 58 cases and a review of the literature[J]. Am J Med, 1981, 70 (3): 493- 505
doi: 10.1016/0002-9343(81)90571-4
[3]   HABIB R , GUBLER M C , HINGLAIS N et al. Alport's syndrome:experience at H?pital Necker[J]. Kidney Int Suppl, 1982, 11:S20- S28
[4]   HERTZ J M . Alport syndrome. Molecular genetic aspects[J]. Dan Med Bull, 2009, 56 (3): 105- 152
[5]   SAVIGE J , GREGORY M , GROSS O et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy[J]. J Am Soc Nephrol, 2013, 24 (3): 364- 375
doi: 10.1681/ASN.2012020148
[6]   NAGEL M , NAGORKA S , GROSS O . Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome[J]. Hum Mutat, 2005, 26 (1): 60
[7]   YAMAMURA T , NOZU K , FU X J et al. Natural history and genotype-phenotype correlation in female X-linked Alport syndrome[J]. Kidney Int Rep, 2017, 2 (5): 850- 855
doi: 10.1016/j.ekir.2017.04.011
[8]   HUDSON B G , TRYGGVASON K , SUNDARA-MOORTHY M et al. Alport's syndrome, Goodpasture's syndrome, and type Ⅳ collagen[J]. N Engl J Med, 2003, 348 (25): 2543- 2556
doi: 10.1056/NEJMra022296
[9]   HAAS M . Alport syndrome and thin glomerular basement membrane nephropathy:a practical approach to diagnosis[J]. Arch Pathol Lab Med, 2009, 133 (2): 224- 232
[10]   MOCHIZUKI T , LEMMINK H H , MARIYAMA M et al. Identification of mutations in the alpha 3(Ⅳ) and alpha 4(Ⅳ) collagen genes in autosomal recessive Alport syndrome[J]. Nat Genet, 1994, 8 (1): 77- 81
doi: 10.1038/ng0994-77
[11]   BARKER D F , HOSTIKKA S L , ZHOU J et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome[J]. Science, 1990, 248 (4960): 1224- 1227
doi: 10.1126/science.2349482
[12]   CROCKETT D K, PONT-KINGDON G, GEDGE F, et al. The Alport syndrome COL4A5 variant database[J/OL]. Hum Mutat, 2010, 31(8): E1652-E1657.
[13]   KROL R P , NOZU K , NAKANISHI K et al. Somatic mosaicism for a mutation of the COL4A5 gene is a cause of mild phenotype male Alport syndrome[J]. Nephrol Dial Transplant, 2008, 23 (8): 2525- 2530
doi: 10.1093/ndt/gfn005
[14]   ALPORT A C . Hereditary familial congenital haemorrhagic nephritis[J]. Br Med J, 1927, 1 (3454): 504- 506
doi: 10.1136/bmj.1.3454.504
[15]   HASSTEDT S J , ATKIN C L , SAN JUAN AC J R . Genetic heterogeneity among kindreds with Alport syndrome[J]. Am J Hum Genet, 1986, 38 (6): 940- 953
[16]   JAIS J P , KNEBELMANN B , GIATRAS I et al. X-linked Alport syndrome:natural history in 195 families and genotype- phenotype correlations in males[J]. J Am Soc Nephrol, 2000, 11 (4): 649- 657
[17]   GROSS O , LICHT C , ANDERS H J et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy[J]. Kidney Int, 2012, 81 (5): 494- 501
doi: 10.1038/ki.2011.407
[18]   WEBB N J , LAM C , SHAHINFAR S et al. Efficacy and safety of losartan in children with Alport syndrome-results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial[J]. Nephrol Dial Transplant, 2011, 26 (8): 2521- 2526
doi: 10.1093/ndt/gfq797
[19]   KASHTAN C E , DING J , GREGORY M et al. Clinical practice recommendations for the treatment of Alport syndrome:a statement of the Alport Syndrome Research Collaborative[J]. Pediatr Nephrol, 2013, 28 (1): 5- 11
doi: 10.1007/s00467-012-2138-4
[20]   SAVIGE J , SHETH S , LEYS A et al. Ocular features in Alport syndrome:pathogenesis and clinical significance[J]. Clin J Am Soc Nephrol, 2015, 10 (4): 703- 709
doi: 10.2215/CJN.10581014
[1] TONG Fan,YANG Rulai,LIU Chang,WU Dingwen,ZHANG Ting,HUANG Xinwen,HONG Fang,QIAN Guling,HUANG Xiaolei,ZHOU Xuelian,SHU Qiang,ZHAO Zhengyan. Screening for hereditary tyrosinemia and genotype analysis in newborns[J]. J Zhejiang Univ (Med Sci), 2019, 48(4): 459-464.
[2] XU Yuqing,QIAN Yeqing,YAO Weimiao,DONG Minyue. Genetic analysis of a family of Van der Woude syndrome[J]. J Zhejiang Univ (Med Sci), 2019, 48(4): 378-383.
[3] LOU Tie,HUANG Yingzhi,DONG Minyue. Genetic study of a family of neuronal ceroid lipofuscinosis caused by a heterozygous mutation of CLN6 gene[J]. J Zhejiang Univ (Med Sci), 2019, 48(4): 373-377.
[4] LIU Bei,YANG Yanmei,YAN Kai,CHEN Min,WANG Liya,HUANG Yingzhi,QIAN Yeqing,DONG Minyue. Genetic analysis and prenatal diagnosis of a sporadic family with neurofibromatosis type 1[J]. J Zhejiang Univ (Med Sci), 2019, 48(4): 367-372.
[5] HONG Pingping,GUO Bingjie,LIN Li,LIN Xihua,ZHOU Jiaqiang. A novel mutation W257R in GCK gene discovered from a Chinese patient with maturity onset diabetes of the young[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 200-203.
[6] XIAO Li,TONG Xiaoyong. Advances in molecular mechanism of vascular remodeling in pulmonary arterial hypertension[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 102-110.
[7] DU Dongfen,ZHU Lixia,WANG Yungui,YE XiujinG. Expression of WT1 gene and its prognostic value in patients with acute myeloid leukemia[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 50-57.
[8] TANG Siyang,YE Jia,LI Yuezhou. I1363T mutation induces the defects in fast inactivation of human skeletal muscle voltage-gated sodium channel[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 12-18.
[9] YIN Li,LI Ge,SHEN Jian,LIU Zhenjie. Screening for inherited thrombophilia and genome sequencing[J]. J Zhejiang Univ (Med Sci), 2018, 47(6): 606-611.
[10] SHI Ting,YE Xiujin. Roles of CCAAT enhancer binding protein α in acute myeloblastic leukemia[J]. J Zhejiang Univ (Med Sci), 2018, 47(5): 552-557.
[11] CHEN Ting,ZHAO Zhengyan,JIANG Pingping,SHU Qiang. Research progress on phenotype and genotype of hyperphenylalaninemia[J]. J Zhejiang Univ (Med Sci), 2018, 47(3): 219-226.
[12] SHEN Jie,CHEN Wendong,JI Kaida,GAO Pingjin,ZHU Dingliang. Effect of Arg188Gln (G/A) mutation on enzymatic activity of kynureninase[J]. J Zhejiang Univ (Med Sci), 2017, 46(6): 643-648.
[13] WANG Mengyan, ZHU Biao. Research progress on genes mutations related to sulfa drug resistance in Pneumocystis jirovecii[J]. J Zhejiang Univ (Med Sci), 2017, 46(5): 563-569.
[14] FANG Minbo, CHEN Qixing, WU Shuijing, FANG Xiangming. Association of single nucleotide polymorphism in exon of transient receptor potential melastatin 2 gene with sepsis[J]. J Zhejiang Univ (Med Sci), 2016, 45(4): 410-415.
[15] XI Xiao-ping, ZENG Ling-xia, Yu Fang-fang, LIU Hua-sheng. Effects of DNMT3A gene mutations on prognosis of patients with acute myeloid leukemia:a meta-analysis[J]. J Zhejiang Univ (Med Sci), 2015, 44(2): 197-203.